Federal Medicaid Agency Directs States to Tighten Autism Therapy Provider Oversight
The guidance signals a shift in how the Centers for Medicare & Medicaid Services weighs cost containment against access to behavioral health services for children with autism — a trade-off with no...
The Centers for Medicare & Medicaid Services (CMS) issued guidance Tuesday directing state Medicaid programs to place new restrictions on providers of Applied Behavior Analysis (ABA) therapy, citing significant growth in Medicaid expenditures for the treatment, according to reporting by The New York Times published August 5, 2026. Caprice Knapp, a senior CMS official, told the Times that the agency had observed a marked increase in costs associated with autism therapy reimbursements and stated the guidance aims to ensure that financial incentives among providers do not override the clinical interests of children receiving care.
ABA therapy is a federally recognized treatment for autism spectrum disorder and is covered under Medicaid's mandatory Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit for children under 21. States are required by federal law under 42 U.S.C. § 1396d(r) to cover all medically necessary services under EPSDT, meaning any state restrictions imposed in response to Tuesday's guidance would need to be carefully designed to avoid running afoul of existing federal statute and court precedent protecting that benefit.
The Trump administration's CMS did not specify in available public reporting the total dollar figure associated with the ABA Medicaid spending increase, nor did it release the full text of the guidance document as of this publication. The agency referenced concerns about waste and fraud as a basis for the advisory, though no specific enforcement actions, audits, or fraud referrals were cited in the publicly available statements. The Government Accountability Office and the HHS Office of Inspector General have both conducted prior reviews of ABA billing practices; their most recent relevant findings would be the appropriate public records to consult for documented fraud rates.
The guidance arrives amid a broader expansion of autism service providers. According to the Times report, thousands of autism clinics have opened across the country in recent years, a growth pattern that correlates with increased Medicaid enrollment and expanded autism diagnosis rates tracked by the Centers for Disease Control and Prevention. Advocacy organizations representing families of children with autism have previously raised concerns that prior authorization requirements and provider restrictions can delay or reduce access to therapies that carry documented clinical support in peer-reviewed literature.
What remains unknown includes the precise dollar amount of the Medicaid ABA spending increase cited by CMS, the specific restrictions states are being advised to implement, and whether the guidance is a formal Information Bulletin — which would be publicly posted on Medicaid.gov — or an informal advisory communication. The full guidance document, once published on Medicaid.gov, would answer these questions. Congressional jurisdiction over this issue rests with the Senate Finance Committee and the House Energy and Commerce Committee, neither of which had issued public statements on the guidance as of this report.